Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
United Therapeutics Releases its Annual Corporate Responsibility Report

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its second annual Corporate Responsibility Report with 2020 highlights, providing stakeholders important...

UTHR : 200.08 (-2.47%)
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021

and , Sept. 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today presented new clinical data from the study evaluating Tyvaso DPI™ (treprostinil) in patients with pulmonary...

UTHR : 200.08 (-2.47%)
MNKD : 4.53 (-0.66%)
United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASToma" in Honor of Childhood Cancer Awareness Month

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it is joining forces with former NFL player and his daughter Leah, a survivor of high-risk neuroblastoma, to launch...

UTHR : 200.08 (-2.47%)
United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present data from a clinical trial studying Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial...

UTHR : 200.08 (-2.47%)
MNKD : 4.53 (-0.66%)
U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics' Tyvaso(R) Patent

Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) against U.S. Patent No. 10,716,793 ('793 patent), owned by...

UTHR : 200.08 (-2.47%)
LQDA : 2.69 (+1.51%)
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up

United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.

MNKD : 4.53 (-0.66%)
LLY : 230.10 (-0.41%)
MDT : 129.70 (-0.93%)
UTHR : 200.08 (-2.47%)
Innovators in Pharma Sectors See Potential, Promise in Providing Improved Treatments

/PRNewswire/ --  in for men and women of most racial and ethnic groups, heart disease is a pervasive health challenge that destroys lives. The Center for Disease Control and Prevention (CDC) reports...

JAZZ : 133.22 (+1.12%)
JNJ : 164.75 (-0.28%)
UTHR : 200.08 (-2.47%)
ABT : 126.79 (-0.51%)
LEXX : 6.32 (+2.93%)
United Therapeutics (UTHR) Q2 Earnings and Revenues Surpass Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 27.62% and 17.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

UTHR : 200.08 (-2.47%)
United Therapeutics: Q2 Earnings Snapshot

SILVER SPRING, Md. (AP) _ United Therapeutics Corp. (UTHR) on Wednesday reported second-quarter net income of $172.6 million.

UTHR : 200.08 (-2.47%)
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results

and , Aug. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the second quarter of 2021...

UTHR : 200.08 (-2.47%)

Barchart Exclusives

US Stock Markets: Stop the Seasonal Madness
A popular theme on financial television these days is September is a seasonally bearish time for US stock markets. The evidence does not support this idea. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar